Company: VRCA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0000950170-25-037172
Chunk: 239

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-03-11
Form: 10-K
Item: Item 8
Chunk 239
---
 on disposal of assets

    83

    2,537

    Total operating expenses

    73,485

    70,883

    Loss from operations

    (65,919
    )

    (65,759
    )

    Other (expense) income:

    Interest income

    1,417

    2,740

    Interest expense

    (9,412
    )

    (3,962
    )

    Change in fair value of derivative liability

    (2,648
    )

    —

    Other expense

    (17
    )

    (14
    )

    Total other expense, net

    (10,660
    )

    (1,236
    )

    Net loss
     
    $
    (76,579
    )
     
    $
    (66,995
    )

    Net loss per share, basic and diluted
     
    $
    (1.48
    )
     
    $
    (1.48
    )

    Weighted-average common shares outstanding, basic and diluted

    51,808,228

    45,342,451

The accompanying notes are an integral part of these financial statements.

95

VERRICA PHARMACEUTICALS INC.

STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

(in thousands, except share amounts)

    Total

    Stockholders'

    Common Stock

    Additional

    Accumulated

    Treasury Stock

    (Deficit)

    Shares Issued

    Amount

    Paid-in Capital

    Deficit

    Shares

    Cost

    Equity

    Balance as of December 31, 2022

    41,199,197

    $
    4

    $
    203,482

    $
    (163,453
    )

    105,144

    $
    —

    $
    40,033

    Stock-based compensation

    —

    —

    14,376

    —

    —

    —

    14,376

    Issuance of common stock and pre-funded warrants, net of issuance costs

    750,000

    —

    30,301

    —

    —

    —

    30,301

    Fair Value of warrants from debt financing

    —

    2,041

    —

    —

    —

    2,041

    Restricted stock vested